Related Experiment Video

Updated: Apr 18, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

7.2K

Discovery and pharmacophore studies of novel pyrazole-based anti-melanoma agents

Qing-Shan Li1, Xian-Hai Lü, Yang Yang

  • 1School of Medical Engineering, Hefei University of Technology, Hefei 230009, P. R. China, (phone/fax: +86-551-62904675); Key Laboratory of Green Pesticide and Agriculture Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, P. R. China. liqs@hfut.edu.cn.

Chemistry & Biodiversity
|February 3, 2015
PubMed

Insights

New pyrazole derivatives show promise for treating malignant melanoma by inhibiting the BRAF(V600E) mutation. Compound 3d demonstrated potent activity, offering a potential new strategy for this dangerous skin cancer.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Molecular Biology

Background:

  • Malignant melanoma is an aggressive skin cancer with limited effective treatments.
  • The BRAF(V600E) mutation is a key driver in melanoma, making it a validated therapeutic target.
  • Novel treatment strategies are urgently needed to combat rising melanoma incidence.

Purpose of the Study:

  • To design, synthesize, and evaluate novel pyrazole derivatives as inhibitors of BRAF(V600E).
  • To identify potent compounds for antimelanoma drug development.
  • To gain insights into structure-activity relationships for further optimization.

Main Methods:

  • In silico screening to identify potential drug candidates.
  • Chemical synthesis of novel pyrazole derivatives.
  • In vitro evaluation of inhibitory activity against BRAF(V600E) melanoma cells.
  • Quantitative Structure-Activity Relationship (QSAR) modeling and docking simulations.

Main Results:

  • Compound 3d exhibited significant inhibitory activity against BRAF(V600E) with an IC50 of 0.63 μM.
  • Compound 3d showed potent growth inhibition (GI50) of 0.61 μM in BRAF(V600E)-dependent cells.
  • QSAR and docking studies provided pharmacophore insights for future drug design.

Conclusions:

  • Novel pyrazole derivatives are effective inhibitors of BRAF(V600E) melanoma.
  • Compound 3d represents a promising lead compound for melanoma therapy.
  • Further structural optimization based on pharmacophore clues could lead to improved antimelanoma agents.
Keywords:
1H-Pyrazoles, 3,5-diaryl-4,5-dihydro-MelanomaNicotinamideQuantitative structureactivity relationship (QSAR)Urea

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.2K

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.6K
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
103